Century Therapeutics (IPSC) Non-Current Assets (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Non-Current Assets data on file, last reported at $187.5 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $187.5 million, up 28.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $522.0 million (down 25.51% YoY), and the FY2025 annual result was $102.9 million, down 35.33% from the prior year.
• Non-Current Assets advanced to $187.5 million in Q1 2026 per IPSC's latest filing, from $102.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $255.9 million in Q2 2023 and troughed at $102.9 million in Q4 2025.
• A 5-year average of $169.8 million and a median of $166.8 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets jumped 71.97% in 2023, then sank 41.53% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $166.8 million in 2022, then increased by 10.11% to $183.7 million in 2023, then slipped by 13.35% to $159.2 million in 2024, then tumbled by 35.33% to $102.9 million in 2025, then jumped by 82.17% to $187.5 million in 2026.
• Business Quant data shows IPSC's Non-Current Assets at $187.5 million in Q1 2026, $102.9 million in Q4 2025, and $107.0 million in Q3 2025.